Axsome Therapeutics (AXSM) Capital Leases (2024 - 2026)

Axsome Therapeutics' Capital Leases history runs 3 years deep, the most recent figure standing at $5.8 million for Q1 2026.

• In Q1 2026, Capital Leases rose 58.8% year-over-year to $5.8 million; the TTM figure through Mar 2026 stood at $5.8 million (up 58.8% YoY), while the FY2025 annual figure was $4.2 million, up 42.92% from the prior year.
• Capital Leases came in at $5.8 million for Q1 2026 at Axsome Therapeutics, up from $4.2 million in the prior quarter.
• In the past five years, Capital Leases ranged from a high of $5.8 million in Q1 2026 to a low of $1.7 million in Q1 2024.
• A 3-year average of $3.6 million and a median of $3.7 million in 2025 frame the typical range for Capital Leases.
• On a YoY basis, Capital Leases climbed as much as 116.85% in 2025 and fell as far as 25.36% in 2025.
• Axsome Therapeutics' Capital Leases stood at $2.9 million in 2024, then surged by 42.92% to $4.2 million in 2025, then surged by 38.94% to $5.8 million in 2026.
• According to Business Quant data, Capital Leases over the past three periods registered $5.8 million, $4.2 million, and $4.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison